Skip to content

ADMA Biologics ADMA Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
Zymeworks logo
ZymeworksZYME
Biohaven logo
BiohavenBHVN
AbbVie logo
AbbVieABBV
Abbott logo
AbbottABT
Danaher logo
DanaherDHR

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's common stock, shares issued (in shares)?
ADMA Biologics (ADMA) reported common stock, shares issued (in shares) of $240.96M in Q1 2026.
How has ADMA Biologics's common stock, shares issued (in shares) changed year-over-year?
ADMA Biologics's common stock, shares issued (in shares) increased by 27715.0% year-over-year, from $866.3K to $240.96M.
What is the long-term trend for ADMA Biologics's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), ADMA Biologics's common stock, shares issued (in shares) has grown at a 18.0% compound annual growth rate (CAGR), from $104.9M to $239.79M.